Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Torsemide + spironolactone** is a fixed-dose combination of two diuretics used primarily to manage edema (fluid retention) and hypertension, especially in patients with heart failure, liver cirrhosis, or kidney disorders[1][3][5][7]. Torsemide is a loop diuretic that works by inhibiting sodium reabsorption in the thick ascending limb of the loop of Henle, resulting in increased urine output and reduced fluid overload. Spironolactone is a potassium-sparing diuretic and a mineralocorticoid receptor antagonist, blocking the action of aldosterone and promoting sodium and water excretion while conserving potassium[1][4][6][8]. The combination provides synergistic diuretic effects while mitigating the risk of hypokalemia typically caused by loop diuretics alone. It is indicated for the treatment of edema due to heart failure, liver cirrhosis, chronic kidney disease, and for hypertension when single diuretic therapy is insufficient[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on torsemide + spironolactone.